We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mind Medicine MindMed Inc | NASDAQ:MNMD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 9.61 | 9.25 | 9.40 | 0 | 01:00:00 |
From Feb 2024 to May 2024
- Data update includes 12-week topline Phase 2b results for MM120 in Generalized Anxiety Disorder (GAD) -
- Results from Phase 1 pharmacokinetics bridging trial for MM120 oral dissolving tablet (ODT) formulation to be discussed -
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a conference call and webcast on March 7, 2024. The program will provide an update on MM120 in Generalized Anxiety Disorder (GAD), including 12-week topline safety, efficacy, and durability results from the Company’s Phase 2b trial and results from the Company’s Phase 1 pharmacokinetics bridging trial to support the advancement of the MM120 oral dissolving tablet (ODT) formulation into pivotal clinical trials.
A live question and answer session will follow the program.
The event will begin at 8:00 a.m. Eastern Time on Thursday, March 7, 2024. The webcast and slides will be accessible live under “News & Events” on the Investors page of the Company’s website at https://ir.mindmed.co/ or by clicking here. A replay of the event will be available on MindMed’s website.
About MM120
Lysergide is a synthetic ergotamine belonging to the group of classic psychedelics, which acts as a partial agonist at human serotonin-2A (5-hydroxytryptamine-2A [5-HT2A]) receptors. MindMed is developing MM120 (lysergide D-tartrate), the tartrate salt form of lysergide, for GAD and other psychiatric indications.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine, and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian Cboe Exchange under the symbol MMED.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240301424341/en/
For Media: media@mindmed.co For Investors: ir@mindmed.co
1 Year Mind Medicine MindMed Chart |
1 Month Mind Medicine MindMed Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
